What is Rosuvas hasan 10?

Rosuvas hasan 10 is a drug that is also commonly used by doctors in clinical practice. However, not everyone knows this drug, so what is Rosuvas hasan 10 drug and how to use this drug?

Rosuvas hasan 10 is produced in the form of tablets, the main ingredient of the drug is Rosuvastatin calcium 10.40 mg equivalent to rosuvastatin 10mg. Rosuvastatin is a selective and competitive inhibitor of HMG-CoA reductase, which catalyzes the conversion of 3-hydroxy-3-methylglutaryl coenzyme A to mevalonate, a cholesterol precursor. The primary site of action of rosuvastatin is in the liver, the target organ of cholesterol lowering. Rosuvastatin has the effect of increasing the number of LDL receptors on the cell surface of the liver, thus increasing the absorption and catabolism of LDL, and inhibiting the synthesis of VLDL in the liver, thereby reducing the components of VLDL and LDL.
Rosuvas Hasan 10 is indicated in the following cases:
Primary hypercholesterolemia (type lla) including heterozygous familial hypercholesterolemia or mixed dyslipidemia (type IIb). Homozygous familial hypercholesterolemia. Rosuvas Hasan 10 is contraindicated in the following cases:
People with hypersensitivity to rosuvastatin or any of its ingredients. Patients with advanced liver disease including unexplained persistent elevations in serum transaminases and when serum transaminase levels are increased more than 3 times normal. Patients with severe renal impairment have creatinine clearance < 30 ml/min. The patient has a muscle disease. The patient is taking cyclosporin, gemfibrozil, cholesterol-lowering fibrates, high-dose niacin (> 1g/day), colchicine, HIV and hepatitis C drugs.

Rosuvas Hasan 10 is used by mouth, patients can take it at any time of the day, during or away from meals.
Before starting treatment with Rosuvas Hasan 10, you need to follow a standard cholesterol-lowering diet and you should continue to maintain this regimen for the duration of treatment. The dose of Rosuvas Hasan 10 drug should be adhered to as prescribed by the doctor. The recommended dose is as follows:
The starting dose is 5 mg or 10 mg orally once daily for both statin-nave patients and for patients switching from another HMG-CoA reductase inhibitor to rosuvastatin. . The choice of starting dose will depend on the individual patient's cholesterol level, future cardiovascular risk, and potential for adverse drug effects.
Your doctor may increase your dose every 4 weeks if needed, up to a maximum dose of 40 mg/day.
For patients with high blood cholesterol at high risk of cardiovascular disease (especially patients with familial hypercholesterolemia) who do not achieve a therapeutic effect at 20mg, the dose can be increased to 40mg and must be regularly monitored by a specialist. The maximum dose of Rosuvas Hasan 10 is 10 mg/day when used in combination with HIV and HCV protease inhibitors such as atazanavir, atazanavir and ritonavir, lopinavir and ritonavir. The safety and efficacy of Rosuvas Hasan 10 in children have not been established. Therefore, the drug Rosuvas Hasan 10 is not recommended for use in children. There is no specific treatment for an overdose of Rosuvas Hasan 10. Therefore, when using an overdose, you should be treated symptomatically and apply supportive measures when necessary.
If you forget a dose of Rosuvas Hasan 10, take it as soon as you remember. However, if it is almost time for your next dose, skip the missed dose and continue with your dosing schedule, do not use a double dose to make up for the missed dose.

When using Rosuvas Hasan 10, you may experience side effects of the drug. However, the side effects of Rosuvas Hasan 10 are usually mild and transient, including:
Headache, dizziness. Constipation, nausea, abdominal pain. Itching, rash and urticaria. Myalgia, myopathy, rhabdomyolysis. Attenuate .

Co-administration of Rosuvas Hasan 10 with cyclosporin, rosuvastatin AUC values ​​were on average 7 times higher than in healthy volunteers, but did not affect plasma concentrations of cyclosporin. Initiating or increasing the dose of Rosuvas Hasan 10 in patients treated concomitantly with vitamin K antagonists (such as warfarin) may increase INR (coagulation index) values. Discontinuing or reducing the dose of Rosuvas Hasan 10 may decrease the INR. In such cases, you should monitor the INR value. Concomitant use of Rosuvas Hasan 10 and Gemfibrozil, other fibrate-lowering agents, high-dose niacin (> 1g/day), colchicine increases the risk of muscle damage. Co-administration of Rosuvas Hasan 10 with an aluminum and magnesium hydroxide antacid suspension reduces plasma concentrations of rosuvastatin by approximately 50%. When taking antacids about 2 hours after taking Rosuvas Hasan 10, plasma concentrations of rosuvastatin will decrease less. Co-administration of Rosuvas Hasan 10 with erythromycin resulted in a 20% decrease in AUC (0 - t) and 30% Cmax of rosuvastatin. Oral contraceptives/hormone replacement therapy (HRT) concomitantly with Rosuvas Hasan 10 increased the AUC of ethinyl estradiol by 26% and the AUC of norgestrel by 34%. Rosuvas Hasan 10 is indicated for the treatment of primary hypercholesterolemia (type lla) including heterozygous familial hypercholesterolemia or mixed dyslipidemia (type IIb). To ensure effective treatment and avoid unwanted side effects, patients need to take the drug exactly as directed by a doctor or pharmacist.
Follow Vinmec International General Hospital website to get more health, nutrition and beauty information to protect the health of yourself and your loved ones in your family.